Medifast, Inc.
MED
NYSE
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -97.90% | -93.89% | -77.93% | -52.20% | -30.75% |
| Total Depreciation and Amortization | -73.17% | -71.00% | 7.80% | 16.37% | 19.37% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 92.56% | 267.80% | 62.45% | -25.46% | -19.12% |
| Change in Net Operating Assets | -148.06% | -131.74% | -117.87% | -107.04% | -6.35% |
| Cash from Operations | -83.42% | -78.85% | -71.63% | -57.72% | -24.11% |
| Capital Expenditure | -14.98% | 58.12% | 56.42% | 60.67% | 61.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 65.06% | 73.86% | -- | -1,479.86% | -1,135.96% |
| Cash from Investing | 56.56% | 69.99% | -325.40% | -424.50% | -434.84% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -80.85% | 13.33% | 13.33% | 13.33% | -- |
| Repurchase of Common Stock | 87.99% | 93.67% | 92.82% | 99.24% | 94.56% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 99.02% | 74.38% | 49.68% | 26.39% | -1.95% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 98.10% | 77.48% | 66.80% | 71.94% | 60.02% |
| Foreign Exchange rate Adjustments | 165.28% | 36.97% | 11.72% | 25.00% | -7.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -152.04% | -94.06% | -145.62% | -557.39% | 140.92% |